US 9809539
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
granted A61KA61K2300/00A61K31/404
Quick answer
US patent 9809539 (Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof) held by Shuttle Pharmaceuticals, Inc. expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Shuttle Pharmaceuticals, Inc.
- Grant date
- Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2300/00, A61K31/404, A61K31/573, A61K45/06